The prospective single-center study on the efficacy and safety of rituximab for the treatment of adult and geriatric patients with primary nephrotic syndrome.
Not Applicable
- Conditions
- primary nephrotic syndrome
- Registration Number
- JPRN-UMIN000022150
- Lead Sponsor
- Tokyo Metropolitan Geriatric Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Case that showed at least one of the following terms should be excluded. 1)Patient who have the severe allergy for rituximab. 2)Patient who has the severe disease, such as heart failure,liver diseases(hepatitis B positive)and end stage renal disease. 3)Patient who has the severe bacterial,fungal or viral infection. 4)Patient who could not experienced informd consent. 5)The doctor decides that the patient is inappropriate to enroll in this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of remission from nephrotic syndrome
- Secondary Outcome Measures
Name Time Method 1.Rate of continuity of the selected treatment. 2. The reduction of the degree of proteinuria. 3. Frequency of adverse complication derived from drug use. 4. Total dose of prednisolone and immunosuppressant agents for treatment of nephrotic syndrome. 5. Changes in the renal function